Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q1 FY26
Arrowhead Pharmaceuticals (ARWR) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 5, 2026
Arrowhead Pharmaceuticals (ARWR) reported revenue of $264M for the first quarter fiscal 2026 (Q1 FY26), up 106-fold from a year earlier and +3% from the quarter before. Operating margin was 15.5%, net earnings $30.8M (11.7% of revenue).
Arrowhead Pharmaceuticals, Q1 FY26: revenue $264M (106× year over year), operating margin 15.5%, net earnings $30.8M, operating cash flow $13.5M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $264M | +3% | 106× |
| Operating profit | $40.8M | -7% | — |
| Net earnings | $30.8M | — | — |
| Operating cash flow | $13.5M | -34% | — |
| Free cash flow | $11.3M | -13% | — |
What changed
Revenue was $264.0M in Q1 FY26, up 10461% year over year and up 3% from the previous quarter.
Operating profit was $40.8M, a 15.5% margin (up 6471.9 points year over year). Total costs grew 36% against revenue growth of 10461%. The fastest-growing cost line was General & admin (+71%). Net earnings were $30.8M ($28.2M including minority interests, which bore $2.6M of losses). The effective tax rate was 0.1%.
Operating cash flow was $13.5M, 48% of net income including minority interests. Non-cash charges added back $6.0M of depreciation and amortization and $19.4M of share-based compensation. Working capital and other items used $40.1M. Capital expenditures of $2.1M left free cash flow of $11.3M.
Questions
What was Arrowhead Pharmaceuticals' revenue in the first quarter fiscal 2026?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $264M for the first quarter fiscal 2026 (Q1 FY26), up 106-fold from a year earlier and +3% from the quarter before.
Was Arrowhead Pharmaceuticals profitable in the first quarter fiscal 2026?
Operating profit was $40.8M (15.5% of revenue) and net earnings $30.8M.